Azvudine for new hepatitis B patients
Part of Digestive system, Infections clinical trials.
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had hepatitis B with a positive surface antigen (HBsAg) and e antigen (HBeAg) for at least 6 months.
- Your HBV DNA (virus level) must be above 20,000 copies/mL, and your HBsAg below 1,500 IU/mL.
- Your ALT (a liver enzyme) must be more than twice the normal upper limit.
- You cannot have taken any antiviral medication for hepatitis B before.
- You cannot have any other liver infections (like hepatitis A, C, D, or E) or HIV.
- You cannot be pregnant, breastfeeding, or planning pregnancy within the next year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
This study tests a two-step approach for chronic hepatitis B: first a shot called AHB-137, followed by another shot called TVAX-008. The goal is to see if this combination can help control the virus better.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.